Context Therapeutics Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Unaudited results cover the three months ended March 31, 2024. Context Therapeutics is a pre-revenue biopharmaceutical company focused on solid tumors. Its lead clinical-stage candidate is CTIM-76, a CLDN6-by-CD3 bispecific antibody designed to direct T cells toward CLDN6-expressing cancer cells. The company discontinued development of ONA-XR in 2023 and is prioritizing CTIM-76.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None reported | No product revenue since inception |
| Research and development expense | $1.97 million | $4.53 million, down 56% |
| General and administrative expense | $1.85 million | $2.13 million, down 13% |
| Operating loss | $3.82 million | $6.67 million |
| Net loss | $3.67 million; $0.23 per share | $6.31 million; $0.40 per share |
| Cash used in operations | $4.36 million | $5.73 million |
| Cash and cash equivalents | $10.09 million at March 31, 2024 | $14.45 million at December 31, 2023 |
| Total current liabilities | $2.61 million | $4.19 million at December 31, 2023 |
| Total debt | No debt balance reported | The company states it has no credit facility or committed capital sources |
No gross or operating margins are meaningful because the company reported no revenue. Accumulated deficit was $71.72 million. Cash equivalents included $9.45 million in money-market accounts. Cash balances exceeded federally insured limits by approximately $9.6 million.
Material changes versus the prior comparable period
- Net loss narrowed by $2.64 million, or 42%, and operating cash use declined by $1.37 million.
- R&D expense fell primarily because Q1 2023 included $2.09 million of ONA-XR costs; no ONA-XR expense was recorded in Q1 2024. CTIM-76 expense declined by approximately $0.20 million, as lower manufacturing costs more than offset higher preclinical, regulatory and clinical preparation costs.
- G&A expense declined by approximately $0.28 million, reflecting lower insurance, professional fees, and compensation and share-based compensation costs.
- On February 29, 2024, the company amended its Integral Molecular license for CTIM-76: development and regulatory milestones were reduced from $55 million to $15 million; sales milestones from $130 million to $12.5 million; and royalties were changed from 8–12% beginning at first commercial sale to 6% on net sales beginning no sooner than February 1, 2034. The amendment also narrowed the license to CTIM-76 and removed certain research-funding reimbursement obligations.
Outlook, risks and other notable items
- Subsequent to quarter-end, the FDA cleared the CTIM-76 IND on May 2, 2024. Management anticipated enrolling the first patient in the Phase 1 dose-escalation trial in mid-2024.
- A May 2024 private placement closed May 6 and raised approximately $100 million gross through 59,032,259 common shares at $1.55 and pre-funded warrants for 5,482,741 shares at $1.549. Estimated offering expenses are $5.2 million. Management expects the proceeds, together with March 31 cash, to fund the planned Phase 1 trial and extend runway into 2028; this estimate depends on assumptions that may prove imprecise.
- The company expects continued operating losses and states that substantial additional funding will be needed to develop and potentially commercialize its candidates. Without financing on acceptable terms, it may delay, reduce or discontinue development. Equity financing may dilute shareholders; other financing or licensing arrangements may require giving up rights or future economics.
- The company identified third-party patents in the United States and certain foreign jurisdictions that potentially cover intellectual property included in CTIM-76 and expire in January 2034. It believes it has reasonable defenses but may not prevail or obtain a license on acceptable terms.
- The company reported no material legal proceedings and no material changes to the risk factors in its 2023 Form 10-K. Management concluded disclosure controls were effective as of March 31, 2024, and reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the Phase 1 trial began on schedule, and subsequent enrollment, safety and clinical progress for CTIM-76.
- Actual net proceeds from the private placement, the full diluted share count after exercise of pre-funded warrants, and the resulting shareholder dilution. The filing reports 74,998,312 common shares outstanding as of May 7, 2024.
- Whether spending and trial costs remain consistent with management’s cash-runway estimate into 2028.
- Any developments regarding the potentially relevant third-party patents, infringement claims or licensing options.
- Progress toward the amended Integral Molecular milestones and the conditions attached to future payments and royalties.